Sanders’ Pressure on Novo Nordisk Fuels Ozempic Pricing Debate

The blockbuster drug Ozempic from Novo Nordisk A/S is the latest target in Sen. Bernie Sanders’ quest to lower drug costs, but it’s unlikely the political pressure campaign will make a dent on the manufacturer to slash prices, some drug pricing observers say.

Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen has yet to publicly respond to Sanders’ (I-Vt.) request to meet this week after the Senate Health, Education, Labor, and Pensions Committee chairman called on the Danish drug company to lower the list price of its drug Ozempic, a weekly injectable used to treat diabetes.

The demand was prompted ...